Product Description
Mechanisms of Action: GLUR Antagonist, Decarboxylase Inhibitor, COMT Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Belgium | France | Germany | Hungary | Ireland | Italy | Korea | Luxembourg | Malta | Netherlands | Portugal | Slovenia | Spain | Switzerland | Turkey | United States
Approved Indications: None
Known Adverse Events: None
Company: Mayo Clinic
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Stroke|Glioma
Phase 2: Thyroid Cancer|Glioma|Glioblastoma|Brain Cancer|Parkinson's Disease|Non-Small-Cell Lung Cancer|Breast Cancer|Melanoma
Phase 1: Congenital Hyperinsulinism|Insulinoma|Glioblastoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04870580 |
FIG | N/A |
Unknown status |
Glioma |
2024-05-01 |
2025-12-02 |
||
NCT00775853 |
09-N-0010 | N/A |
Completed |
Pure Autonomic Failure|Parkinson's Disease |
2023-01-11 |
2025-09-20 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT02538315 |
Bio 15-21 | N/A |
Terminated |
Parkinson's Disease |
2018-09-01 |
2023-06-03 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
NCT02539433 |
F-DOPA | N/A |
Completed |
Neuroendocrine Tumors |
2015-05-01 |
2019-03-20 |
||
NCT02021604 |
NCT02021604 | P1 |
Recruiting |
Insulinoma|Congenital Hyperinsulinism |
2028-01-01 |
2019-03-20 |
Treatments |
|
NCT04315584 |
HSR190096 | P1 |
Recruiting |
Glioblastoma |
2023-12-20 |
2020-03-27 |
Primary Endpoints|Treatments|Trial Status |
|
NCT06667726 |
NCI-2024-08915 | P2 |
Not yet recruiting |
Brain Cancer |
2029-10-08 |
2025-03-19 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date |
|
NCT05781321 |
SAGA | P2 |
Active, not recruiting |
Glioblastoma |
2026-07-02 |
2025-09-10 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2024-515850-26-00 |
ICO-202-28 DOPACER | P2 |
Recruiting |
Melanoma|Brain Cancer|Non-Small-Cell Lung Cancer|Breast Cancer |
2026-03-03 |
2025-05-02 |
Treatments |
|
NCT04459052 |
FdopaPD2 | P2 |
Active, not recruiting |
Parkinson's Disease |
2025-04-11 |
2025-07-30 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
2021-001017-37 |
DOPACER | P2 |
Unknown status |
Breast Cancer|Non-Small-Cell Lung Cancer|Melanoma|Brain Cancer |
2023-08-24 |
2025-06-19 |
Treatments |
|
NCT03242824 |
MC167B | P2 |
Completed |
Glioma |
2020-06-16 |
2023-03-15 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT01991977 |
MC1374 | P2 |
Completed |
Glioma |
2019-07-01 |
2025-04-17 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2006-005356-33 |
DOPMET | P2 |
Active, not recruiting |
Thyroid Cancer |
2010-01-19 |
2022-03-12 |
Treatments |
|
2022-501688-42-00 |
2021PI203 | P3 |
Recruiting |
Glioma |
2026-08-01 |
2025-05-02 |
Treatments |
|
2024-518721-15-00 |
2024-518721-15-00 | P3 |
Recruiting |
Stroke |
2025-05-13 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|